Macrophages, inflammation, and insulin resistance

Annual Review of Physiology

Volumn 72, Issue , 2009, Pages 219-246

  Olefsky, Jerrold M ^a   Glass, Christopher K ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adipose tissue; Kupffer cell; Obesity; Skeletal muscle

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; CHEMOKINE; DOCOSAHEXAENOIC ACID; ETANERCEPT; FATTY ACID; GLUCOSE; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALICYLIC ACID; SALSALATE; STAT6 PROTEIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; ANTIINFLAMMATORY AGENT;

ADAPTIVE IMMUNITY; ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DRUG MECHANISM; DRUG MEGADOSE; ENDOPLASMIC RETICULUM; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; HEREDITY; HUMAN; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER; MACROPHAGE; MACROPHAGE ACTIVATION; MEDIATOR; METABOLIC SYNDROME X; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POLARIZATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TARGET CELL; ANIMAL; GENETICS; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ADIPOSE TISSUE; ANIMALS; ANTI-INFLAMMATORY AGENTS; DIABETES MELLITUS, TYPE 2; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIVER; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, TRANSGENIC; MUSCLE, SKELETAL; OBESITY; PPAR GAMMA; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 77951918926     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021909-135846     Document Type: Review

References (155)

1. Schenk S, Saberi M, Olefsky JM. 2008. Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Investig. 118:2992-3002
2. Wellen KE, Hotamisligil GS. 2005. Inflammation, stress, and diabetes. J. Clin. Investig. 115:1111-1119
3. Heilbronn LK, Campbell LV. 2008. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr. Pharm. Des. 14:1225-1230
4. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. 2003. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Investig. 112:1796-1808
5. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Investig. 112:1821-1830
6. Dabelea D, Hamman RF. 2004. Epidemiology of type 2 diabetes mellitus. In Type 2 Diabetes Mellitus: A Fundamental and Clinical Text, ed.DLeRoith, SITaylor, JMOlefsky, pp. 785-796 Philadelphia: Lippincott Williams &Wilkins
7. Reaven GM. 2005. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu. Rev. Nutr. 25:391-406
8. Olefsky JM, Courtney CH. 2005. Type 2 diabetes mellitus: etiology, pathogenesis, and natural history. In DeGroot Textbook of Endocrinology, 5th ed, ed. LJ DeGroot, JL Jameson, D deKrestser, AB Grossman, JC Marshall, et al., ch. 56, pp. 1093-1117 Philadelphia: WB Saunders and Co.
9. Weir GC, Leahy JL. 1 994. Pathogenesis of noninsulin dependent (type II) diabetes mellitus. In Joslin's Diabetes Mellitus, ed. GR Kahn, GCWeir, pp. 240-264 Philadelphia: Lea & Febiger/Waverly
10. Stumvoll M, Goldstein BJ, van Haeften TW. 2005. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333-1346
11. Facchini FS, Hua N, Abbasi F, Reaven GM. 2001. Insulin resistance as a predictor of age-related diseases. J. Clin. Endocrinol. Metab. 86:3574-3578
12. Olefsky JM, Kruszynska YT. 2002. Insulin resistance. In Ellenberg & Rifkin's Diabetes Mellitus, ed. D Porte Jr, RS Sherwin, A Baron, pp. 367-400. New York: McGraw-Hill
13. Kaprio J, Tuomilehto J, Koskenvuo M, Romanov K, Reunanen A, et al. 1992. Concordance for type 1 (insulin-dependent) and type 2 (noninsulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia 35:1060-1067
14. Newman B, Selby JV, King MC, Slemenda C, Fabsitz R, Friedman GD. 1987. Concordance for type 2 (noninsulin-dependent) diabetes mellitus in male twins. Diabetologia 30:763-768
15. Groop L, Forsblom C, Lehtovirta M, Tuomi T, Karanko S, et al. 1996. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes 45:1585-1593
16. Manolio TA, Brooks LD, Collins FS. 2008. A HapMap harvest of insights into the genetics of common disease. J. Clin. Investig. 118:1590-1605
17. Lyssenko V, Groop L. 2009. Genome-wide association study for type 2 diabetes: clinical applications. Curr. Opin. Lipidol. 20:87-91
18. Goldstein DB. 2009. Common genetic variation and human traits. N. Engl. J. Med. 360:1696-1698
19. Hirschhorn JN. 2009. Genomewide association studies-illuminating biologic pathways. N. Engl. J. Med. 360:1699-1701
20. Kraft P, Hunter DJ. 2009. Genetic risk prediction-Are we there yet? N. Engl. J. Med. 360:1701-1703
21. Chen Y, Zhu J, Lum PY, Yang X, Pinto S, et al. 2008. Variations in DNA elucidate molecular networks that cause disease. Nature 452:429-435
22. Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, et al. 2008. Genetics of gene expression and its effect on disease. Nature 452:423-428
23. Yang X, Deignan JL, Qi H, Zhu J, Qian S, et al. 2009. Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks. Nat. Genet. 41:415-423
24. Wang P, Mariman E, Renes J, Keijer J. 2008. The secretory function of adipocytes in the physiology of white adipose tissue. J. Cell Physiol. 216:3-13
25. Scherer PE. 2006. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 55:1537-1545
26. Halberg N, Wernstedt-Asterholm I, Scherer PE. 2008. The adipocyte as an endocrine cell. Endocrinol. Metab. Clin. N. Am. 37:753-68, x-xi
27. Tajiri Y, Mimura K, Umeda F. 2005. High-sensitivity C-reactive protein in Japanese patients with type 2 diabetes. Obes. Res. 13:1810-1816
28. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. 1995. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Investig. 95:2409-2415
29. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, et al. 2001. The hormone resistin links obesity to diabetes. Nature 409:307-312
30. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, et al. 2005. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436:356-362
31. Chen A, Mumick S, Zhang C, Lamb J, Dai H, et al. 2005. Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes. Res. 13:1311-1320
32. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, et al. 2006. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Investig. 116:115-124
33. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, et al. 2002. A central role for JNK in obesity and insulin resistance. Nature 420:333-336
34. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. 2005. Increased p85/55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes 54:2351-2359
35. Itani SI, Ruderman NB, Schmieder F, Boden G. 2002. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and I -α. Diabetes 51:2005-2011
36. Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, et al. 2007. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 282:35279-35292
37. Solinas G, Vilcu C, Neels JG, Bandyopadhyay GK, Luo JL, et al. 2007. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab. 6:386-397
38. Arkan MC,Hevener AL, Greten FR, Maeda S, Li ZW, et al. 2005. IKK-β links inflammation to obesityinduced insulin resistance. Nat. Med. 11:191-198
39. Shoelson SE, Lee J, Goldfine AB. 2006. Inflammation and insulin resistance. J. Clin. Investig. 116:1793-1801
40. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, et al. 2002. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Investig. 109:1321-1326
41. Hotamisligil GS, Shargill NS, Spiegelman BM. 1993. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259:87-91
42. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, et al. 2005. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat. Med. 11:183-190
43. Shoelson SE, Lee J, Yuan M. 2003. Inflammation and the IKKβ/I-β/NF-κB axis in obesity-and dietinduced insulin resistance. Int. J. Obes. Relat. Metab. Disord. 27(Suppl. 3):S49-52
44. Qi Y, Nie Z, Lee YS, Singhal NS, Scherer PE, et al. 2006. Loss of resistin improves glucose homeostasis in leptin deficiency. Diabetes 55:3083-3090
45. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, et al. 2004. Regulation of fasted blood glucose by resistin. Science 303:1195-1198
46. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, et al. 2001. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-γ action in humans. Diabetes 50:2199-2202
47. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, et al. 2003. Resistin is expressed in human macrophages and directly regulated by PPARγ activators. Biochem. Biophys. Res. Commun. 300:472-476
48. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. 2004. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med. 1:e45
49. Qatanani M, Szwergold NR, Greaves DR, Ahima RS, Lazar MA. 2009. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J. Clin. Investig. 119:531-539
50. Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, et al. 2008. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesitymediated insulin resistance. Arterioscler. Thromb. Vasc. Biol. 28:1304-1310
51. Sultan A, Strodthoff D, Robertson AK, Paulsson-Berne G, Fauconnier J, et al. 2009. T cell-mediated inflammation in adipose tissue does not cause insulin resistance in hyperlipidemic mice. Circ. Res. 104:961-968
52. Rocha VZ, Folco EJ, Sukhova G, Shimizu K, Gotsman I, et al. 2008. Interferon-γ, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ. Res. 103:467-476
53. Winer S, Chan Y, Paltser G, Truong D, Tsui H, et al. 2009. Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 15:921-929
54. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, et al. 2009. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 15:914-920
55. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, et al. 2009. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15:930-939
56. Elgazar-Carmon V, Rudich A, Hadad N, Levy R. 2008. Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. J. Lipid Res. 49:1894-1903
57. Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG. 2008. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell. Metab. 8:301-309
58. Vallabhapurapu S, Karin M. 2009. Regulation and function of NF-κB transcription factors in the immune system. Annu. Rev. Immunol. 27:693-733
59. Bennett BL, Satoh Y, Lewis AJ. 2003. JNK: a new therapeutic target for diabetes. Curr. Opin. Pharmacol. 3:420-425
60. Ogawa S, Lozach J, Jepsen K, Sawka-Verhelle D, Perissi V, et al. 2004. A nuclear receptor corepressor transcriptional checkpoint controlling activator protein 1-dependent gene networks required for macrophage activation. Proc. Natl. Acad. Sci. USA 101:14461-14466
61. Huang W, Ghisletti S, Perissi V, Rosenfeld MG, Glass CK. 2009. Transcriptional integration of TLR2 and TLR4 signaling at the NCoR depression checkpoint. Mol. Cell 35:48-57
62. Chang L, Chiang SH, Saltiel AR. 2004. Insulin signaling and the regulation of glucose transport. Mol. Med. 10:65-71
63. Lesniewski LA, Hosch SE, Neels JG, de Luca C, Pashmforoush M, et al. 2007. Bone marrow-specific Cap gene deletion protects against high-fat diet-induced insulin resistance. Nat. Med. 13:455-462
64. Feral CC, Neels JG, Kummer C, Slepak M, Olefsky JM, Ginsberg MH. 2008. Blockade of α4 integrin signaling ameliorates the metabolic consequences of high-fat diet-induced obesity. Diabetes 57:1842-1851
65. Kanda H,Tateya S,Tamori Y, Kotani K, Hiasa K, et al. 2006. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Investig. 116:1494-1505
66. Inouye KE, Shi H, Howard JK, Daly CH, Lord GM, et al. 2007. Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 56:2242-2250
67. Gregor MG,Hotamisligil GS. 2007. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J. Lipid Res. 48:1905-1914
68. Ron D, Walter P. 2007. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8:519-529
69. Eizirik DL, Cardozo AK, Cnop M. 2008. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr. Rev. 29:42-61
70. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, et al. 2004. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306:457-461
71. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, et al. 2006. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313:1137-1140
72. Yoshiuchi K, Kaneto H, MatsuokaTA, Kohno K, Iwawaki T, et al. 2008. Direct monitoring of in vivo ER stress during the development of insulin resistance with ER stress-activated indicator transgenic mice. Biochem. Biophys. Res. Commun. 366:545-550
73. Furuhashi M, Fucho R, Gorgun CZ,Tuncman G, Cao H, Hotamisligil GS. 2008. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J. Clin. Investig. 118:2640-2650
74. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. 2007. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 56:16-23
75. Lumeng CN, Bodzin JL, Saltiel AR. 2007. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Investig. 117:175-184
76. Gordon S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3:23-35
77. Song MJ, Kim KH, Yoon JM, Kim JB. 2006. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem. Biophys. Res. Commun. 346:739-745
78. Lee JY, Sohn KH, Rhee SH,Hwang D. 2001. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 276:16683-16689
79. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. 2006. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Investig. 116:3015-3025
80. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, et al. 2007. Loss-offunction mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 56:1986-1998
81. Saberi M, Woods N-B, Luca C, Schnek S, Chin J, et al. 2009. Hematopoeitic cell specific deletion of Toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high fat-fed mice. Cell Metab. In press
82. Chawla A, Repa J, Evans R, Mangelsdorf D. 2001. Nuclear receptors and lipid physiology: opening the X-files. Science 294:1866-1870 (Pubitemid 33101573)
83. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. 1998. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79-82
84. Ricote M, Huang J, Fajas L, Li A,Welch J, et al. 1998. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA 95:7614-7619
85. Jiang C,TingAT, Seed B. 1998. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86
86. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. 1998. Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisomal proliferator-activated receptor γ expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am. J. Pathol. 153:17-23
87. Hevener AL, Olefsky JM, Reichart D, Nguyen MT, Bandyopadyhay G, et al. 2007. Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Investig. 117:1658-1669
88. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH,Morel CR, Subramanian V, et al. 2007. Macrophagespecific PPARγ controls alternative activation and improves insulin resistance. Nature 447:1116-1120
89. Marathe C, Bradley MN, Hong C, Chao L,Wilpitz D, et al. 2009. Preserved glucose tolerance in highfat-fed C57BL/6 mice transplanted with PPARγ -/-, PPARδ -/-, PPARγδ -/-, or LXRαβ -/-bone marrow. J. Lipid Res. 50:214-224
90. Kang K, Reilly SM, Karabacak V, Gangl MR, Fitzgerald K, et al. 2008. Adipocyte-derived Th2 cytokines and myeloid PPARδ regulate macrophage polarization and insulin sensitivity. Cell Metab. 7:485-495
91. Goldin A, Beckman JA, Schmidt AM, Creager MA. 2006. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114:597-605
92. Schmidt AM, Yan SD, Wautier JL, Stern D. 1999. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84:489-497
93. Bucciarelli LG,Wendt T, Rong L, Lalla E, Hofmann MA, et al. 2002. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol. Life Sci. 59:1117-1128
94. Huttunen HJ, Fages C, Rauvala H. 1999. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem. 274:19919-19924
95. Webster L, Abordo EA, Thornalley PJ, Limb GA. 1997. Induction ofTNFα and IL-1βmRNAin monocytes by methylglyoxal-and advanced glycated endproduct-modified human serum albumin. Biochem. Soc. Trans. 25:S250
96. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, et al. 2006. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 26:2716-2723
97. Takeda K, Akira S. 2007. Toll-like receptors. Curr. Protoc. Immunol. Chapter 14:Unit 14.12
98. Medzhitov R. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1:135-145
99. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. 2009. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458:1191-1195
100. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088
101. Takeda K, Akira S. 2005. Toll-like receptors in innate immunity. Int. Immunol. 17:1-14
102. Omueti KO, Beyer JM, Johnson CM,Lyle EA,Tapping RI. 2005. Domain exchange between human tolllike receptors 1 and 6 reveals a region required for lipopeptide discrimination. J. Biol. Chem. 280:36616-36625
103. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, et al. 2005. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 46:2347-2355
104. Black PR, Brooks DC, Bessey PQ, Wolfe RR, Wilmore DW. 1982. Mechanisms of insulin resistance following injury. Ann. Surg. 196:420-435
105. Wolowczuk I, Verwaerde C, Viltart O, Delanoye A, Delacre M, et al. 2008. Feeding our immune system: impact on metabolism. Clin. Dev. Immunol. 2008:639803
106. Schuster DP, Brody SL, Zhou Z, Bernstein M, Arch R, et al. 2007. Regulation of lipopolysaccharideinduced increases in neutrophil glucose uptake. Am. J. Physiol. Lung Cell Mol. Physiol. 292:L845-51
107. Amar J, Burcelin R, Ruidavets JB, Cani PD, Fauvel J, et al. 2008. Energy intake is associated with endotoxemia in apparently healthy men. Am. J. Clin. Nutr. 87:1219-1223
108. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, et al. 2007. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 292:E740-47
109. Backhed F, Ding H,Wang T, Hooper LV, Koh GY, et al. 2004. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA 101:15718-15723
110. Nau GJ, Richmond JF, Schlesinger A, Jennings EG, Lander ES, Young RA. 2002. Human macrophage activation programs induced by bacterial pathogens. Proc. Natl. Acad. Sci. USA 99:1503-1508
111. Takeda K, Akira S. 2004. TLR signaling pathways. Semin. Immunol. 16:3-9
112. Werner SL, Barken D, Hoffmann A. 2005. Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science 309:1857-1861
113. Baud V, Karin M. 2001. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11:372-377
114. Noppert SJ, Fitzgerald KA, Hertzog PJ. 2007. The role of type I interferons in TLR responses. Immunol. Cell Biol. 85:446-457
115. Ghisletti S, Huang W, Ogawa S, Pascual G, Lin ME, et al. 2007. Parallel SUMOylation-dependent pathways mediate gene-and signal-specific transrepression by LXRs and PPARγ. Mol. Cell 25:57-70
116. Ogawa S, Lozach J, Benner C, Pascual G, Tangirala RK, et al. 2005. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122:707-721
117. Ghisletti S, Huang W, Jepsen K, Benner C, Hardiman G, et al. 2009. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev. 23:681-693
118. Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG. 2004. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 116:511-526
119. Guenther M, Lane W, Fischle W, Verdin E, Lazar M. 2000. A Core SMRT corepressor complex containing HDAC3 and TBL1, aWD40-repeat protein linked to deafness. Genes Dev. 14:1048-1057
120. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, et al. 2005. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 437:759-763
121. Chun J, Prince A. 2006. Activation of Ca2+-dependent signaling by TLR2. J. Immunol. 177:1330-1337
122. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, et al. 2007. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712-716
123. Hoffmann A, Levchenko A, Scott ML, Baltimore D. 2002. The I-β-NF-κB signaling module: temporal control and selective gene activation. Science 298:1241-1245
124. Gilchrist M, Thorsson V, Li B, Rust AG, Korb M, et al. 2006. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 441:173-178
125. Saijo K,Winner B, Carson CT, Collier JG, Boyer L, et al. 2009. ANurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137:47-59
126. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, et al. 2004. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060-1067
127. Lemke G, Rothlin CV. 2008. Immunobiology of the TAM receptors. Nat. Rev. Immunol. 8:327-336
128. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. 2007. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131:1124-1136
129. Camenisch TD, Koller BH, Earp HS, Matsushima GK. 1999. A novel receptor tyrosine kinase, Mer, inhibits TNF-α production and lipopolysaccharide- induced endotoxic shock. J. Immunol. 162:3498-3503
130. Sharif MN, Sosic D, Rothlin CV, Kelly E, Lemke G, et al. 2006. Twist mediates suppression of inflammation by type I IFNs and Axl. J. Exp. Med. 203:1891-1901
131. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, et al. 2000. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723-1732
132. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. 2004. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem. Biophys. Res. Commun. 323:630-635
133. Yamaguchi N, Argueta JG, Masuhiro Y, Kagishita M, Nonaka K, et al. 2005. Adiponectin inhibits Tolllike receptor family-induced signaling. FEBS Lett. 579:6821-6826
134. Neumeier M, Weigert J, Schaffler A, Wehrwein G, Muller-Ladner U, et al. 2006. Different effects of adiponectin isoforms in human monocytic cells. J. Leukoc. Biol. 79:803-808
135. Huang H, Park PH, McMullen MR, Nagy LE. 2008. Mechanisms for the anti-inflammatory effects of adiponectin in macrophages. J. Gastroenterol. Hepatol. 23(Suppl. 1):S50-53
136. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 1995. 15-Deoxy-D12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-812
137. Straus DS, Pascual G, Li M,Welch JS, Ricote M, et al. 2000. 15-deoxy-δ 12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl. Acad. Sci. USA 97:4844-4849
138. Bell-Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, FitzGerald GA. 2003. Biosynthesis of 15-deoxy-δ12,14-PGJ2 and the ligation of PPARγ. J. Clin. Investig. 112:945-955
139. Ariel A, Serhan CN. 2007. Resolvins and protectins in the termination program of acute inflammation. Trends Immunol. 28:176-183
140. Lee JY, Plakidas A, Lee WH, Heikkinen A, Chanmugam P, et al. 2003. Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J. Lipid Res. 44:479-486
141. Neschen S, Morino K, Dong J, Wang-Fischer Y, Cline GW, et al. 2007. n-3 fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-α-dependent manner. Diabetes 56:1034-1041
142. Huang JT,Welch JS, Ricote M, Binder CJ,WillsonTM,et al. 1999. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 400:378-382
143. Vats D, Mukundan L, Odegaard JI, Zhang L, Smith KL, et al. 2006. Oxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation. Cell Metab. 4:13-24
144. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH,Morel CR, Subramanian V, et al. 2007. Macrophagespecific PPARγ controls alternative activation and improves insulin resistance. Nature 447:1116-1120
145. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, et al. 2008. Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity-induced insulin resistance. Cell Metab. 7:496-507
146. Barish GD, Downes M, Alaynick WA, Yu RT, Ocampo CB, et al. 2005. A nuclear receptor atlas: macrophage activation. Mol. Endocrinol. 19:2466-2477
147. Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. 2006. Effects of etanercept in patients with the metabolic syndrome. Arch. Intern. Med. 166:902-908
148. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, et al. 2007. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356:1517-1526
149. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, et al. 2001. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of IKKβ. Science 293:1673-1677
150. Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, et al. 2008. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin. Transl. Sci. 1:36-43
151. Lehmann JM,Moore LB, Smith-Oliver TA,Wilkison WO,Willson TM, Kliewer SA. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270:12953-12956
152. Spiegelman BM. 1998. PPARγ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514
153. He W, Barak Y, Hevener A, Olson P, Liao D, et al. 2003. Adipose-specific peroxisome proliferatoractivated receptor γ knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. USA 100:15712-15717
154. Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, et al. 2003. Muscle-specific PPARγ deletion causes insulin resistance. Nat. Med. 9:1491-1497
155. Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, et al. 2003. Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Investig. 112:608-618